PRMT1 can reduce calcium/calmodulin‐dependent protein kinase II (CaMKII) activity by methylating arginine residues (e.g., R9 and R275) of CaMKII, hence inhibiting arrhythmia and cardiac hypertrophy resulting from excessive CaMKII activation. This evidence concerns the gene CAMK2G and cardiac hypertrophy.